Registration Options

Activity Date: 04/07/2024

Sign in (or create a FREE account) to access this FREE session!

Session Time and Location

The live session is complete.

Session Summary

Modulation of dopamine levels in key brain areas affected in schizophrenia has historically been achieved by using dopamine D2 receptor antagonists. Although such D2 receptor blockade may ameliorate positive symptoms of schizophrenia, it often comes at the cost of high motor side effect risk and lack of efficacy for treating the non-positive symptoms of schizophrenia. In this presentation, the speaker will bring to light the intricate neurocircuitry affecting dopaminergic neurotransmission as it relates to schizophrenia. With this understanding, potential utilization of novel agents to modulate dopamine levels without directly affecting dopamine D2 receptors will be discussed and evaluated.


The bookmark/discussion system is temporarily disabled. Please check back later.

Grant Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. 


Claim Credits

The program evaluation and CME certificate will be available on April 7, 2024.

  1. Create a new account at or use your existing account
  2. Complete your evaluation at
  3. Download or print your certificate

Questions? email or phone 888-535-5600 (Mon-Fri: 9am5pm Pacific)